Abstract
We report a retrospective analysis of a nationwide health database to study the association between sodium-glucose cotransporter-2 inhibitor (SGLT2I) use and the incidence of adverse clinical outcomes among heart failure (HF) patients with and without atrial fibrillation (AF) stratified by CHA2DS2–VASc score. The outcome of this study was on the development of adverse events, including acute myocardial infarction (AMI), hemorrhagic stroke, ischemic stroke, cardiovascular (CV) death, and all-cause mortality. By dividing the number of adverse events by the total person-years, the incidence rate was calculated. The hazard ratio (HR) was estimated by the Cox proportional hazard model. A total of 95% confidence interval (CI) was also presented to show the risk of adverse events for HF patients with and without AF taking SGLT2I. SGLT2I users had a lower risk of AMI (adjusted HR = 0.83; 95% CI = 0.74, 0.94), CV death (adjusted HR = 0.47; 95% CI = 0.42, 0.51), and all-cause death (adjusted HR = 0.39; 95% CI = 0.37, 0.41). Considering HF patients without AF and SGLT2I as the reference group, HF patients without AF but with SGLT2I had a reduced risk of adverse outcomes of 0.48 (95% CI = 0.45, 0.50), and HF patients with AF and SGLT2I had the decreased hazard ratio of 0.55 (95% CI = 0.50, 0.61). The adjusted HR of adverse outcomes for HF patients with CHA2DS2–VASc score less than 2 and SGLT2I without and with AF relative to HF patients without AF nor SGLT2I were 0.53 (95% CI = 0.41, 0.67) and 0.24 (95% CI = 0.12, 0.47), respectively. Compared to HF patients with no history of AF and SGLT2I, if patients additionally with SGLT2I and CHA2DS2–VASc score ≥ 2, the risk of the adverse outcomes was reduced with adjusted HR of 0.48 (95% CI = 0.45, 0.50); if patients additionally with AF and CHA2DS2–VASc score ≥ 2, the risk of the adverse outcomes was decreased with adjusted HR of 0.88 (95% CI = 0.80, 0.97); if patients additionally with AF, SGLT2I, and CHA2DS2–VASc score ≥ 2, the risk of the adverse outcomes was diminished with adjusted HR of 0.52 (95% CI = 0.47, 0.58). We concluded that SGLT2I has a protective effect in HF patients, and the risk reduction is greater with a score of < 2 and without AF.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
Data are available upon reasonable request.
References
Anter E, Jessup M, Callans DJ (2009) Atrial fibrillation and heart failure: treatment considerations for a dual epidemic. Circulation 119(18):2516–2525
Ferreira JP, Santos M (2015) Heart failure and atrial fibrillation: from basic science to clinical practice. Int J Mol Sci. 16(2):3133–47
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW (2022) 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation 145(18):e895–e1032
Hu WS, Lin CL (2017) CHA2DS2-VASc score in the prediction of ischemic bowel disease among patients with atrial fibrillation: insights from a nationwide cohort. Int J Cardiol Int J Cardiol 15(235):56–60
Hu WS, Lin CL (2019a) Acute coronary syndrome, ischemic stroke and mortality prediction in patients with heart failure: a comparison of CHA2DS2-VASc and AHEAD scores. J Interv Card Electrophysiol 55(2):225–231
Hu WS, Lin CL (2019b) Comparison of CHA2DS2-VASc and AHEAD scores for the prediction of incident dementia in patients hospitalized for heart failure: a nationwide cohort study. Intern Emerg Med 14(3):395–402
Hu WS, Lin CL (2022) Weekend vs. weekday admission and clinical outcomes in heart failure patients with and without atrial fibrillation in Taiwan. Eur Heart J Cardiovasc Pharmacother 8(4):346–352
Kotecha D, Piccini JP (2015) Atrial fibrillation in heart failure: what should we do? Eur Heart J 36(46):3250–7
Li S, Vandvik PO, Lytvyn L, Guyatt GH, Palmer SC, Rodriguez-Gutierrez R, Foroutan F, Agoritsas T, Siemieniuk RAC, Walsh M, Frere L, Tunnicliffe DJ, Nagler EV, Manja V, Åsvold BO, Jha V, Vermandere M, Gariani K, Zhao Q, Ren Y, Cartwright EJ, Gee P, Wickes A, Ferns L, Wright R, Li L, Hao Q, Mustafa RA (2021) SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline. BMJ 11(373):n1091
Lubitz SA, Benjamin EJ, Ellinor PT (2010) Atrial fibrillation in congestive heart failure. Heart Fail Clin. 6(2):187–200
McMurray JJV, DeMets DL, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Bengtsson O, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD, DAPA-HF committees and investigators (2019) A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). Eur J Heart Fail. 21(5):665–675. https://doi.org/10.1002/ejhf.1432
Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, Böhm M, Choi DJ, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-La Rocca HP, Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde MF, Spinar J, Squire I, Taddei S, Wanner C, Zannad F, EMPEROR-reduced trial investigators (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 383(15):1413–1424. https://doi.org/10.1056/NEJMoa2022190
Yaşar E, Akalın Y, Aktaş İ, Çakmak T, Karakuş Y, Bayramoğlu A (2022a) The CHA2DS2-VASc risk score predicts successful endovascular treatment in patients with acute ischemic stroke. Acta Neurol Scand 145(4):407–413
Yaşar E, Bayramoğlu A, Karakuş Y, Çakmak T (2022b) The CHA2DS2-VASc risk score predicts total occlusion in infarct-related arteries in patients with non-ST elevation myocardial infarction. Angiology 73(4):380–386
Funding
This study was supported in part by the Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW109-TDU-B-212–114004), China Medical University (CMU110-AWARD-01), and China Medical University Hospital (DMR-HHC-110–4, DMR-112–009).
Author information
Authors and Affiliations
Contributions
All authors contributed to the manuscript. All were involved in the design of the study, collected the data, performed statistical analysis, and wrote the manuscript, and all authors were involved in the final approval of the manuscript.
Corresponding author
Ethics declarations
Ethical approval
This study was approved by the Institutional Review Board of China Medical University Hospital Research Ethics Committee (CMUH109-REC2-031(CR-2)).
Consent to participate
Not required.
Consent for publication
Not required.
Competing interests
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Hu, WS., Lin, CL. Clinical outcomes in heart failure patients with and without atrial fibrillation receiving sodium-glucose cotransporter-2 inhibitor. Naunyn-Schmiedeberg's Arch Pharmacol 396, 1977–1986 (2023). https://doi.org/10.1007/s00210-023-02425-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00210-023-02425-5